End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.49 CNY | +4.17% | +6.14% | -3.19% |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 65% by 2026.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.19% | 1.44B | - | ||
+1.69% | 12.8B | B+ | ||
-7.57% | 7.61B | B- | ||
+3.22% | 5.41B | B | ||
+0.93% | 4.51B | C | ||
+8.48% | 4.49B | C | ||
+9.21% | 2.73B | - | - | |
-13.87% | 2.02B | B- | ||
-11.63% | 1.73B | D+ | ||
+3.45% | 1.64B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300406 Stock
- Ratings Beijing Strong Biotechnologies,Inc.